Neurocrine Biosciences (NBIX) EBIT Margin (2010 - 2026)
Neurocrine Biosciences' EBIT Margin was 15.80% in Q2 2026, down 5.38 percentage points from 21.18% a year earlier and down 7.95 percentage points from the prior quarter.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) EBIT Margin (2010 - 2026) Analysis & Trends
On a trailing twelve-month basis, Neurocrine Biosciences' EBIT Margin was 23.56% through Jun 30, 2026, up 3.84 percentage points year-over-year; for FY2025, it was 21.64%, down 2.58 percentage points from FY2024.
- EBIT Margin shows a five-year change of +6.06 percentage points (FY2020 to FY2025).
- In earlier years, EBIT Margin was 24.22% in FY2024 (+10.93 pp), 13.30% in FY2023 (-3.43 pp), 16.73% in FY2022 (+7.68 pp) and 9.04% in FY2021 (-6.54 pp).
- The Q2 2026 figure marks the lowest quarterly EBIT Margin since Q1 2025.
- Compared with a year earlier, EBIT Margin was higher in four of the last eight quarters, with an average year-over-year change of -0.70 percentage points.
- The best year-over-year quarter for EBIT Margin over five years was Q1 2024 (a gain of 46.43 percentage points); the worst was Q4 2021 (a drop of 40.60 percentage points).
- Per Business Quant data, NBIX's EBIT Margin in the three quarters before Q2 2026 was 23.74% (Q1 2026), 26.18% (Q4 2025) and 30.07% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 28.37% |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 37.40% |
| 10 | Neurocrine Biosciences | 14.41 Bn | 10.11 Bn | 935.80 Mn | 15.80% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 15.80% |
| Mar 31, 2026 | 23.74% |
| Dec 31, 2025 | 26.18% |
| Sep 30, 2025 | 30.07% |
| Jun 30, 2025 | 21.18% |
| Mar 31, 2025 | 4.12% |
| Dec 31, 2024 | 22.62% |
| Sep 30, 2024 | 29.55% |
| Jun 30, 2024 | 24.64% |
| Mar 31, 2024 | 19.27% |
| Dec 31, 2023 | 29.17% |
| Sep 30, 2023 | 28.31% |
| Jun 30, 2023 | 16.26% |
| Mar 31, 2023 | -27.16% |
| Dec 31, 2022 | 25.10% |
| Sep 30, 2022 | 22.63% |
| Jun 30, 2022 | 14.46% |
| Mar 31, 2022 | 1.00% |
| Dec 31, 2021 | -11.63% |
| Sep 30, 2021 | 15.03% |
API Access
Neurocrine Biosciences EBIT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebit-margin&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebit-margin", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebit-margin&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();